key: cord-1007791-go5azaqi authors: Rodrigues Guimarães Alves, Vitória; Kleber de Souza Luna, Luciano; Santiago Cruz, Jessica; Helena Perosa, Ana; Bellei, Nancy title: Influenza B viral load analysis in patients with acute respiratory infection from a tertiary hospital in Brazil date: 2019-12-09 journal: J Med Virol DOI: 10.1002/jmv.25648 sha: de80cb6cf383c4f89d1208ae5a078f7b83915cca doc_id: 1007791 cord_uid: go5azaqi Currently, 2 genotypes of Influenza B viruses (IFB) are cocirculating in humans: Victoria (VIC) and Yamagata (YAM). Infection and viral load (VL) were analyzed in 105 genotyped IFB (59 VIC and 46 YAM) out of 3452 respiratory samples from immunodepressed (ID), immunocompetent (IC) including outpatients (OP) and hospitalized patients (HP) attended during 2001‐2013 at São Paulo Hospital. VL (Log(10) RNA copies/mL) calculation was possible in 78 samples (47 VIC, 31 YAM). The age group of 12 to 18 years presented the highest detection (14.13%). Rates of infection among groups were of 3.67% (IC), 1.68% (ID), 3.50% (OP), 0.6% (HP), and VLs varied from 2.8 to 10.13 with no difference regarding age, immune status, and disease severity. From 10 OP vaccinated against influenza, 8 (7 children, 1 ID) received a matching strain shot (VIC), and 2 a monovalent influenza A H1N1pdm09. Those patients presented a VL of 6.31 ± 1.62 (mean ± SD). IFB infection rates follow an age pattern, but VL seems not to be related to frequency or clinical outcome. IFB patients with previous immunization could point to some protection for VIC infections since there was no HP. Other immunological aspects, such as lineage infection immune priming, previous infections, and vaccinations, should be further investigated. Those patients presented a VL of 6.31 ± 1.62 (mean ± SD). IFB infection rates follow an age pattern, but VL seems not to be related to frequency or clinical outcome. IFB patients with previous immunization could point to some protection for VIC infections since there was no HP. Other immunological aspects, such as lineage infection immune priming, previous infections, and vaccinations, should be further investigated. Oseltamivir was the first of this class to be released, followed by zanamivir and finally peramivir. In Brazil, the Ministry of Health recommends the use of oseltamivir and zanamivir for treatment of influenza infections. [5] [6] [7] [8] Oseltamivir previously showed a lower clinical efficacy against IFB and, particularly, lower effectiveness in young children. There are limitations for zanamivir prescription and a lack of other antiviral drug classes for influenza treatment in the market. Furthermore, a recent study showed that IFB susceptibility for baloxavir (inhibitor of the viral RNA polymerase) was approximately 3-fold lower than the observed for influenza A viruses. In this regard, it is important to understand the pathophysiology of IFB viruses and disease progression to access the best management for each patient. For this purpose, understanding the viral load (VL) dynamics may consist of an essential tool to deal with episodes of influenza viral infection. [9] [10] [11] This study aimed to evaluate the rate of infection and VL quantification in positive IFB genotyped samples in different patient groups attended at a tertiary hospital in Brazil. RNA extraction of samples was carried out using the QIAmp Viral RNA Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer's recommendations. IFB one-step real-time RT-PCR detection and further lineage differentiation were conducted as described elsewhere. 13 Figure 1 ). When comparing immunocompetent children (n = 33, 0-12 years) and adults (n = 57, ≥13 years), both presented similar mean VLs (6.53 ± 1.6, and 6.6 ± 1.75 Log 10 RNA copies/mL, respectively), with no statistical difference between them (p = 0.88). Rates of infection by patient condition and group were of 3.67% (IC), 1.68% (ID), 3.50% (OP), and 0.6% (HP). VLs varied from 2.8 to 10.13 Log 10 RNA copies/mL (mean ± SD: 6.33 ± 1.75) (Table 2, Figure 2 ). However, no statistically significant differences were observed considering immune status (immunosuppression), disease severity (outpatient vs inpatient), lineage type or age (children vs adults). On this regard (children vs adults), VL values within patient groups were, respectively, as follows: ID, 5.43 ± 3.78 and 5.42 ± 1.8; IC, 6.53 ± 1.57 and 6.56 ± 1.75; HP, 6.31 ± 1.72 and 6.27 ± 2.44; and OP, 6.6 ± 1.55 and 6.64 ± 1.45. No statistical differences were found related to lineage distribution among analyzed groups (p = .69). General mean VL of infections caused by VIC (n = 47) and YAM (n = 31) were of 6.4 ± 1.8 and 6.3 ± 1.9. Within all IFB positive patients, 10 (9.17%) of them had received a previous influenza vaccination: 8 (7 children between 1 to 9 years and 1 ID) were shot with a vaccine strain that matched the circulating Informe Técnico: 20ª Campanha Nacional de Vacinação contra a Influenza virus infections in humans Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983 The rationale for quadrivalent influenza vaccines Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses Competitive fitness of influenza B viruses possessing E119A and H274Y neuraminidase inhibitor resistance-associated substitutions in ferrets Peramivir injection in the treatment of acute influenza: a review of the literature Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance Development of an efficient qRT-PCR assay for quality control and cellular quantification of respiratory samples WHO Interim Global Surveillance Standards for influenza 2012 Detection of influenza B lineages from 2001 to 2013 in a tertiary hospital in the city of Sao Paulo, Brazil Pandemic A(H1N1)2009 influenza virus detection by real time RT-PCR: is viral quantification useful? Evolutionary pattern of reemerging influenza B/Victoria lineage viruses in Sao Paulo, Brazil, 1996-2012: implications for vaccine composition strategy Characteristics and outcomes of young children hospitalized with laboratory-confirmed influenza or respiratory syncytial virus in Ontario, Canada Epidemiology of influenza B/ Yamagata and B/Victoria lineages in South Africa Influenza and rhinovirus viral load and disease severity in upper respiratory tract infections Influenza virus surveillance among young children in Sao Paulo, Brazil: the impact of vaccination Influenza B viral load analysis in patients with acute respiratory infection from a tertiary hospital in Brazil The authors declare that they have no conflicts of interest. http://orcid.org/0000-0002-